The Palo Alto, California-based company, now valued at $120 million, has developed a scalable way to quickly generate crucial biological data needed for AI models–and use them to find new cures for cancer.
Related Posts
“Alien: Earth” — a prequel series set before the original “Alien” movie — begins streaming and launches on cable this…
Looking for help with today’s New York Times Wordle? Here are some expert hints, clues and commentary to help you…
Canelo vs. Crawford headlines Netflix’s Sept. 13 card, but Callum Walsh, Fernando Vargas Jr., and Christian Mbilli will also be…
Looking for help with today’s NYT Strands puzzle? Here’s an extra hint to help you uncover the right words, as…
The demand for electricity from artificial intelligence is climbing faster than the nation’s grid can keep up, and Congressman Robert…
Many users prefer ChatGPT 4’s warmth and expressiveness over GPT 5’s restrained tone. Sam Altman admits deprecating old models hurt…
Salesforce’s backing can provide Datumo with several benefits, including the possibility of working with the company on its AI agents…
Ford promised a Model-T moment. Will they hit the right mix to sell the public?
Major cloud providers and Apple are building their own alternatives to Nvidia, Its not working out well,
Security leaders Brian Murphy and James Lowry share how AI “teammates” are transforming SOCs, reducing burnout, and enabling faster, more…